Clostridium difficile-associated-diarrhea (CDAD) is a nosocomial infection in dogs. Diagnosis of this infection is dependent on clinical signs of disease supported by laboratory detection of C. difficile toxins A or B, or both, in fecal specimens via enzyme-linked immunosorbent assay (ELISA). Unfortunately, to the authors' knowledge, commercially available ELISAs have not been validated in dogs to date. We evaluated 5 ELISAs done on 143 canine fecal specimens (100 diarrheic and 43 nondiarrheic dogs) and on 29 C. difficile isolates. The results of each ELISA were compared with the cytotoxin B tissue culture assay (CTA). Clostridium difficile was isolated from 23% of the fecal specimens. Eighteen of the 143 fecal specimens were toxin positive (15 diarrheic and 3 nondiarrheic dogs). On the basis of multiplex polymerase chain reaction (PCR) analysis for toxin-A and -B genes, 72% of the isolates were toxigenic. The carriage rate of toxigenic isolates in diarrheic dogs was higher than that in the nondiarrheic dogs; however, these differences were not statistically significant. A good correlation was found between CTA, PCR, and culture results. The ELISAs done on fecal specimens collected from diarrheic dogs had low sensitivity (7-33%). In contrast, ELISA for toxin A or B, or both, performed on toxigenic isolates had high sensitivity (93%). These results suggest that commercially available human ELISAs are inadequate for the diagnosis of canine C. difficile-associated diarrhea when tested on fecal specimens. In contrast, the Premier ToxinA/B and Techlab ToxinA/B ELISAs may be useful for the diagnosis of canine CDAD when used on toxigenic isolates.
Introduction
Clostridium difficile is a large gram-positive, anaerobic, spore-forming, motile rod known to be the main etiologic agent of nosocomial diarrhea in hospitalized human patients, 16, 32, 34 and is an important cause of pseudomembranous colitis. Most isolates from C. difficile-associated gastrointestinal tract disease can produce up to 5 toxins, 8 but only 2 toxins are known to be responsible for the virulence: toxin A, an enterotoxin, and toxin B, a potent cytotoxin. Strains are classified as toxigenic or nontoxigenic on the basis of production of these 2 toxins. A strain of C. difficile lacking at least part of the toxin-A gene has been isolated. 37 The isolation of toxin A(2) toxin B(+) strains also has been reported. 1, 2, 31 The role of C. difficile in diarrheic dogs is not well defined, and the association of antibiotic exposure with C. difficile isolation and toxin detection in canine fecal specimens unfortunately is still unclear. 7, 9, 27, 35 Toxigenic C. difficile has been isolated from dogs with chronic diarrhea, 6 and reports have documented a variable carriage rate of C. difficile ranging from 0-40% in diarrheic and nondiarrheic dogs. 9, 26, 35, 40 Despite the lack of a significant difference in the isolation rates of C. difficile in diarrheic and nondiarrheic dogs, an association has been documented between the presence of diarrhea and detection of toxin A or B, or both, in canine fecal specimens. 26, 40 An apparent outbreak of enteric disease in a small animal veterinary teaching hospital associated with C. difficile toxin A or B, or both has been reported. 39 The fecal ELISAs for toxin A or B, or both, are the main clinical tests used for diagnosis of C. difficileassociated diarrhea 13, 22 and, though it is not a ''gold standard'' (perfect sensitivity and specificity), the tissue culture cytotoxicin-B assay (CTA) has been used as the reference test. 4, 41 The CTA has high sensitivity (94-100%) and specificity (99%) 4, 5, 13, 15, 23, 39 ; however, it is relatively expensive, time consuming, and requires 2-3 days for confirmation of negative results. The sensitivities and specificities of the ELISAs validated for humans vary widely when evaluated in different laboratories (33-95% and 66-100%, respectively) 3, 23, 29 ; however, to the authors' knowledge, none of these ELISA kits have been validated for canine fecal specimens to date, and there is no standard ELISA used at veterinary diagnostic laboratories. In addition, reports have indicated a high number of false-positive ELISA toxin results in canine fecal specimens that were culture negative. 40 The objective of the study reported here was to evaluate the performance characteristics of 5 ELISAs commonly used in humans for detection of C. difficile toxin A or B, or both, in 143 canine fecal specimens (100 diarrheic and 43 nondiarrheic dogs), and in 29 C. difficile isolates cultured from 29 fecal specimens. Sensitivities and specificities of the tests were estimated relative to the cytotoxin-B assay as the reference test. 4, 5, 13, 15, 23, 39 
Materials and methods
Fecal specimens were prospectively collected from 143 diarrheic and nondiarrheic dogs over an 8-mo period. Age of the diarrheic dogs (n 5 100) ranged between 7 mo and 12 yr (mean, 5.3 yr; median, 5 yr), and that of the nondiarrheic dogs (n 5 43) ranged between 7 mo and 13 yr (mean, 3.3 yr; median, 5.5 yr). All diarrheic dogs were presented to the Veterinary Medical Teaching Hospital (VMTH) at the University of California, Davis, or at 2 small animal veterinary practices located within 10 min of the VMTH. All nondiarrheic dogs were healthy dogs owned by veterinary students and staff at the VMTH, and the dogs had no history of gastrointestinal tract disease within 6 months prior to fecal specimen collection. All diarrheic fecal specimens were collected from dogs at the respective hospitals prior to overnight hospitalization. All fecal specimens were naturally voided and were immediately collected and processed within 2 hr at the Companion Animal Gastrointestinal Laboratory in the VMTH. Fecal specimens were evaluated for the presence of C. difficile on selective culture medium, and for C. difficile toxin A or B, or both, via ELISA, and for cytotoxin B via CTA. Polymerase chain reaction analysis was performed on isolates to identify toxigenic strains.
Isolation of C. difficile
Fecal specimens were cultured on prereduced selective medium containing cycloserine-cefoxitin-fructose agar (CCFA). a Plates were incubated anaerobically at 37uC for 72 hr. Plates were examined for the presence of nonswarming yellow colonies exhibiting a ground glass appearance. Yellow colonies were subcultured to prereduced Brucella agar (BA), a and were incubated anaerobically for 24 hr at 37uC. Colonies were subjected to Gram staining. Identification of C. difficile was made on the basis of lack of aerotolerance, colony morphology, fluorescence, odor, and detection of L-proline-aminopeptidase b on CCFA and BA.
Enzyme immunoassays
Five enzyme-linked immunoassays (ELISAs) were used in this study: C. difficile toxA&B c ; Premier C. difficile Toxin A&B and Premier Toxin A d ; Triage Micro C. difficile panel Toxin A & common antigen (glutamate dehydrogenase (GD) e ; and ColorPac Toxin A. f All ELISAs were performed according to the manufacturers' recommendations. Color development was determined spectrophotometrically using an ELISA microplate reader g set at 450 nm, except for the ColorPac Toxin A and Triage Micro C. difficile Toxin A assays, in which fecal specimens with any band development were considered to have positive results.
Twenty-nine C. difficile isolates from 29 canine fecal specimens were further evaluated for the presence of toxin A or B, or both, by use of the 5 ELISAs, CTA, and PCR analysis. All ELISAs were performed twice: once using only 2-4 colonies, and once using 7-10 colonies. These assays were performed on small colonies at 24 hr of incubation on BA medium. a
Cytotoxicin B assay (CTA)
All fecal specimens were diluted 1:10 in phosphatebuffered saline (pH 7.0), vortexed, centrifuged at 4,90 3 g for 15 min at 20uC to pellet debris, and the supernatant was filtered though a 0.22-mm pore size syringe filter unit. The filtered sample, with and without polyclonal anti-C. difficile toxin B anti-toxin (C. difficile Toxin A/B II), c was added to a confluent layer of human foreskin fibroblast (HFF) h cells and was observed for a cytopathic effect (CPE). A specimen was considered positive for toxin B if at least 30% of the HFF cells were rounded, and the effect was neutralized by C. difficile antitoxin after 24 hr of incubation. Specimens with negative results were incubated and results were read again at 48 hr. Clostridium difficile toxin B (C. difficile Toxin A/B II), with and without anti-toxin, was used as the positive and negative control, respectively. 11
Polymerase chain reaction detection of toxin A and toxin B genes
Clostridium difficile isolates were cultured on BA medium and incubated anaerobically for 72 hr. The DNA was extracted by boiling colonies in 200 ml of deionized distilled H 2 O for 20 min and centrifuging at 20,000 3 g for 5 min. One microliter (50-200 ng) of supernatant was used as template. The sequences of the primers used have been described elsewhere. 18, 36 The reaction mixture was prepared in 13 PCR buffer (1.5 mM MgCl, 0.2 mM each deoxynucleoside triphosphate, 0.5 mM each primer, and 4 U of Taq polymerase). 17, 18 All amplifications were done for 34 cycles in a DNA thermal cycler. i
Statistical analysis
Sensitivities and specificities for the 5 ELISAs were estimated using the CTA as the reference test. 4, 5, 13, 15, 23, 39 Sensitivity of the ELISA done on fecal specimens or fecal isolates was defined as the conditional probability of testing positive for C. difficile toxin A or B via ELISA among diarrheic, toxin-positive dogs (CTA positive), whereas specificity was defined as the conditional probability of testing negative for C. difficile toxin A or B via ELISA among fecal or isolate CTA-negative dogs. Isolation of C. difficile, identification of toxigenic isolates, and identification of C. difficile toxin B in diarrheic and nondiarrheic dogs were compared using a chi-square test. A value of P , 0.05 was considered statistically significant.
Results

Isolation and PCR analysis of C. difficile
Clostridium difficile was isolated from 33 of 143 fecal specimens (23%), of which 20 were isolated from diarrheic dogs (20%), and 13 were isolated from nondiarrheic dogs (30%) ( Table 1 ). These differences were not statistically significant (P 5 0.18). Multiplex PCR analysis for toxin-A and -B gene sequences was positive for 24 of 33 isolates (72.7%). Sixteen of the 20 (80%) culture-positive, diarrheic dogs had toxigenic isolates, and 8 of 13 (62%) culture-positive, nondiarrheic dogs had toxigenic isolates (Table 1 ). These differences were not significantly different (P 5 0.24).
Cytotoxicin B assay (CTA)
Eighteen of 143 fecal specimens (12.6%) were positive for C. difficile toxin B by results of CTA. The cytotoxin-B assay was positive for 15 fecal specimens collected from 100 diarrheic dogs (15%) and for 3 fecal specimens collected from 43 nondiarrheic dogs (7%) ( Table 1 ). The CPE was confirmed positive for 14 of the 15 toxin B-positive diarrheic specimens at 48 hours, and 1 was confirmed positive at 24 hours. The latter specimen also was positive by use of all 5 ELISAs. The CPE was confirmed positive after 48 hours for the 3 nondiarrheic specimens. All fecal specimens that were CTA negative and CCFA positive were confirmed CTA negative on testing of C. difficile isolates. One fecal specimen was CTA negative; however, the isolate recovered from this specimen was CTA positive. The latter result was confirmed on retesting of the isolate. Retesting of the fecal specimen from this dog was not possible because of insufficient sample volume. Seventeen of the 18 CTA-positive specimens also were culture positive on CCFA, and CPE was observed on the isolates via CTA. The presence of toxin-A and -B gene sequences were confirmed by results of PCR analysis. In this study, only 1 fecal specimen was toxin positive, but was negative on culture using CCFA medium.
The ELISAs done on fecal specimens
Sixty of 143 fecal specimens were positive by 1 or more of the 5 ELISAs, and only 1 fecal specimen was positive by all 5 ELISAs, was positive on culture, and was CTA positive ( Table 2 ). The sensitivity for all ELISAs for diarrheic dogs ranged from 7 to 33%, and specificity ranged from 65 to 100% ( Table 2) . The sensitivity and specificity of the Triage Biosite for detection of C. difficile GD was 60 and 98%, respectively ( Table 2 ).
The ELISAs done on C. difficile isolates
Twenty-nine of the 33 C. difficile isolates cultured from 143 fecal specimens were recovered from skim milk medium, but we were unable to recover 4 of the 33 isolates. All isolates were analyzed by use of the 5 ELISAs and by the CTA. The CTA of 2-4 colonies was positive for 15 isolates, 14 of which were positive by CTA of fecal specimens. The CTA of 2-4 colonies was negative for 14 isolates, all of which also were negative for fecal specimens. The Premier toxin A/B ELISA was positive for 14 of the 29 isolates and was negative for 15 isolates. All of the ELISA-positive isolates were positive by CTA, and 14 of 15 ELISAnegative isolates also were negative by use of the CTA. The Techlab toxA/B ELISA was positive for 15 of the 29 isolates and was negative for 14 isolates. Thirteen of the 15 positive isolates were positive by CTA, and 13 of the 14 negative ELISAs were negative by CTA. All 29 isolates tested were positive for GD using the Triage Biosite test. All results of the Premier Toxin A, BD Toxin A, and Triage Toxin A tests were negative when tested on 2-4 colonies. All 5 ELISAs were used to retest additional colonies (7-10) to see whether the results were reproducible, and results were identical for 4 of the 5 ELISAs, with the exception of the Premier Toxin A test, which identified 12 positive isolates that also were also positive by the CTA of fecal specimens, and 17 negative isolates, of which 14 were negative by the CTA of fecal specimens. One fecal specimen was CTA negative, but toxin B was detected in the C. difficile isolates when they were tested by CTA and ELISA. The sensitivities and specificities were higher for the ELISAs that detected toxins A and B when testing of toxigenic isolates, compared with testing of fecal specimens. The sensitivity of the Techlab toxin A/B and Premier toxin A/B when testing of isolates was 93% for both assays, and specificity was 87 and 100%, respectively. The Biosite Triage was positive for GD for all 29 isolates tested, and had sensitivity of 100%.
Discussion
The overall isolation rates of Clostridium difficile from the dogs of this study (23%), and the isolation rates from diarrheic dogs (20%) and nondiarrheic dogs (30%) were in agreement with previous reports in which significant differences were not found in the isolation rates of C. difficile between the 2 groups. 26, 35 The majority of C. difficile strains (73%) were toxigenic on the basis of results of the multiplex PCR assay for identification of toxin-A and -B gene sequences. The carriage rates of toxigenic isolates in diarrheic dogs (80%) was higher than those in nondiarrheic dogs (62%); however, these differences were not significant (P 5 0.24). These finding are in agreement with those reported in previous studies. 25, 38 In this study, the prevalence of C. difficile toxin B detected via CTA on fecal specimens from diarrheic dogs (15%) was slightly lower than that previously published (21%), 26, 40 and the detection of toxin B was not significantly associated with the presence of diarrhea (P 5 0.18). Two previous reports in veterinary literature documented an association between the presence of toxin B and diarrhea in dogs; however, both studies determined the presence of toxins A or B, or both, via ELISA, not CTA, potentially biasing the results toward an association of toxin B and diarrhea. 26, 40 In the study reported here, the CTA was used as the reference method for detecting the presence of toxin B in fecal specimens, and caution should be heeded in comparing results of ELISA versus cytotoxin B testing of canine fecal specimens. It is highly likely that previous studies determining the presence of toxin A or B, or both, via ELISA were associated with a high incidence of falsepositive results. This impression is substantiated by results of a recent study, which indicated that a large number of dogs were negative on fecal culture for C. difficile, but were positive via ELISA for toxin A or B, or both. 40 In the study reported here, only 1 fecal specimen was toxin positive, but was negative on culture using CCFA medium. It is plausible that sampling problems inherent to the uneven distribution of C. difficile in the fecal specimen may have contributed to this result.
The results of this study confirmed the low sensitivity of all 5 ELISAs when performed on fecal specimens and compared with the reference test (CTA). In contrast, the sensitivity and specificity of the ELISAs for toxins A and B were higher when tested on isolates rather than fecal specimens. One fecal specimen was CTA negative, but the toxin was detected from isolates via CTA. It has been speculated that toxin degradation by fecal proteases could result in weak cytotoxin activity in fecal specimens from cases of C. difficile-associated colitis. 17 The detection of toxin B in the isolate despite the inability to detect the toxin in the fecal specimen should be interpreted with caution, as toxin production in vitro does not automatically imply that toxin is produced and secreted in the intestinal tract. 33 This point remains the subject of controversy despite several studies evaluating this phenomenon. 18, 33 The low sensitivity of the ELISAs for use with canine fecal specimens is in contrast to the performance characteristics of the assays for use with human feces, 12, 28, 29, 38 and suggests that these tests that are commonly used for laboratory diagnosis of CDAD in humans are unacceptable for testing canine feces. The main problem in coproantigen detection by ELISA is the false-negative and false-positive results, compared with the ''gold standard.'' The high number of false negatives by ELISA obtained by us may be explained by 3 important factors: 1) presence of an inhibitor in canine fecal specimens that may reduce the specificity of binding; 2) presence of protease activity that has been reported as a reason for toxin degradation 17 ; and 3) low levels of toxin may not be detected by the ELISAs. 14 In humans, symptoms of CDAD usually develop when 10 4 -10 5 colony-forming units (CFUs) of C. difficile/g of feces are present. 14 There are no data about the threshold of C. difficile CFUs in dogs that will induce clinical signs of disease. It is noteworthy that the only fecal specimen that tested positive using all of the ELISAs was the one with a positive CTA result at 24 hours, and the CPE was observed in .90% of the cells. The remaining 17 fecal specimens were CTA positive at 24 and 48 hours, and only 30-90% of cells had CPE. Further analysis needs to be performed in diarrheic dogs to determine whether a correlation exists between the titer of toxin in feces and the severity of CDAD. The high number of false-positive reactions associated with the Techlab ELISA for canine feces may be explained by a secondary nonspecific binding of fecal proteins to the primary polyclonal antibody used in this ELISA. Results of a previous study indicated nonspecific binding in rodent fecal specimens when tested by a commercially available human ELISA for rotavirus. That study indicated that this nonspecific binding was related to a protein found in the diets of rats and mice. 21 It also is important to recognize that, in the absence of a perfect reference test, differential misclassification of true C. difficile status between ELISA-positive and -negative samples can lead to an over-or underestimation of C. difficile prevalence, with the magnitude of the error dependent on the respective false-positive and falsenegative proportions of true infection status, as well as sensitivity and specificity of the ELISA.
The major risk factor for CDAD in humans and horses is the previous use of antimicrobials. 6, 14, 19 The carriage rate of C. difficile and toxins in animals including dogs that had recently received antibiotics was higher than that in the nonantibiotic-treated group, although these differences were not statistical-ly significant. 9 Another study indicated that the presence of C. difficile in canine feces is evident only after administration of antibiotic. 27 All fecal specimens examined by us were derived from dogs that had not received antibiotics for at least 2 weeks prior to fecal specimen collection. Results of several studies support the notion that antimicrobial treatment is not required for CDAD development in dogs, and the concurrent use of antibiotics is not significantly different between dogs that were C. difficile positive or negative, and between the toxigenic and nontoxigenic isolates. 26, 35, 40 The CTA correlated highly with ELISA results for toxins A and B on toxigenic isolates. In contrast, all ELISA toxin-A test results for C. difficile isolates were negative when tested on 2-4 colonies, even when C. difficile was isolated from specimens that were CTA positive. These results were either false negatives, or the isolates were toxin-A negative and toxin-B positive. However, when 7-10 colonies were tested, a positive reading was obtained by use of the Premier Toxin A ELISA. In these assays, the colonies used were small, because the isolates were studied after 24 hours' incubation in BA culture medium. This could be explained by the finding that more toxin A is associated with more numerous colonies. The higher sensitivity of Toxin A/B ELISA versus Toxin A ELISA may be explained by its ability to detect toxins A and B, rather than just toxin A, or the toxigenic strains of C. difficile may produce toxin A and B in roughly equivalent amounts. 25 Recent reports of clinically noteworthy isolates of C. difficile in humans 1,2,31 and horses 24 indicated a lack of large segments of the toxin-A gene that codes for the clostridial repetitive oligopeptide region (CROP). These isolates have been referred to as toxin A(2) toxin B(+) strains. Such strains of C. difficile yield negative results when tested by methods that use monoclonal antibodies that bind only the CROP region of Toxin A. 2 These toxin A(2) toxin B(+) strains have been found to be highly virulent in the animal model. 10 No toxinotyping (mapping different areas of toxins A and B) was performed in study reported here. To date, such toxin variant strains in canine C. difficile isolates have not been reported; however, the potential role of these variant strains cannot be dismissed in dogs. In addition, the interpretation of toxin A(2) and toxin B (+) strains seems more complex than just the presence or absence of the toxA gene. 30 The results of this study suggest that C. difficile could be an important part of the normal intestinal microflora in dogs on the basis of the nonsignificant difference in the isolation rate of C. difficile between diarrheic and nondiarrheic dogs. Whether host factors or microbial factors are important in the development of CDAD in dogs is not known. This is in agreement with recent reports, in which C. difficile toxin was detected in 53.3% of healthy human adults who had not been hospitalized during the preceding few years and had not received any antibiotics during the preceding few months. 20 Those authors suggested that the presence of C. difficile in human gut microbiota is higher than that previously suspected. Additional studies are warranted to determine whether differences in toxin-B prevalence exist in diarrheic and nondiarrheic dogs after antibiotic administration.
In conclusion, results of this study indicate that ELISAs validated for use with human samples for detection of C. difficile toxins should not be used for canine fecal specimens due to the unacceptably low sensitivity. This finding is important because all veterinary reference laboratories and veterinary teaching hospitals rely on these assays for detecting C. difficile toxins in canine fecal specimens, resulting in high incidence of false-negative results. The CTA remains the most sensitive and specific assay for the diagnosis of CDAD by use of canine feces; however, this assay is infrequently performed in human laboratories, and is not performed in veterinary laboratories because it is labor intensive and technically demanding. The diagnostic yield is increased when the TechLab toxA/B or Premier Toxin A&B ELISAs are used on toxigenic isolates. The results of this study underscore the importance of developing canine-specific ELISAs for the detection of C. difficile toxins in canine feces.
